Zhitong Finance App News, Shiyao Group (01093) announced that the SYS 6062 developed by the Group has been approved by the China National Drug Administration and can conduct clinical trials in China.

This product is a monoclonal antibody conjugate drug that binds to specific receptors on the surface of tumor cells, enters the cell through endocytosis and releases toxins, thereby killing tumor cells. This product is declared as a therapeutic biological product category 1, and the approved indication is advanced solid tumors.

Preclinical studies have shown that the product has anti-tumor effects on various types of cancer, and is expected to show good curative effects in subsequent clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.